| Name | Title | Contact Details |
|---|
American Nuclear Insurers (ANI) is a joint underwriting association created by some of the largest insurance companies in the United States. Our purpose is to pool the financial assets pledged by our member companies to provide the significant amount of property and liability insurance required for nuclear power plants and related facilities throughout the world.
Weekes Forest Products, Inc. (WEEKES) is a St. Paul, Minnesota based wholesaler and distributor of wood products and building materials. Founded in 1978, WEEKES has grown to become one of the most successful independently-owned distributors in the United States. Financial Data. WEEKES has earned a reputation as a highly entrepreneurial, sales-driven company with a history of financial success. WEEKES has 8 regional locations. Seven of these enterprises were the result of acquisitions WEEKES has completed since 1986. In the United States, many local and regional distribution companies could add to WEEKES growth. The Company plans to grow internally as well as through future acquisition(s). WEEKES FOREST PRODUCTS LOCATIONS Fargo, ND 800-548-2479 St. Paul, MN 800-328-2890 Green Bay, WI 800-236-6314 Milwaukee, WI 800-222-4698 Chicago, IL 800-398-8266 Grand Rapids, MI 800-442-8082 Tampa, FL-Logan Lumber Co. 800-365-5545 Corporate Culture. WEEKES is an informal, value-driven company where honesty, straight communication, and mutual respect are important. Teamwork, good product knowledge, strong work ethic and cost control are keys to the success of the company.
ODP Business Solutions, LLC, an operating company of The ODP Corporation (NASDAQ:ODP), is a leading B2B provider of workplace and technology solutions, combining an extensive range of products and services with a national footprint and hundreds of experienced business advisors. As a trusted partner, ODP Business Solutions supports over 120,000 corporate clients with navigating the often complex needs of todays business environment. From accessing comprehensive solutions and strategic alliances, to supply chain innovation and robust digital platforms, ODP Business Solutions helps customers achieve business results across every industry. #ODPBusinessSolutions #workplacesolutions #technologysolutions #B2Bprovider
Le groupe international Ondura est spécialisé dans les solutions détanchéité pour les bâtiments et regroupe des entreprises leaders dans leurs domaines : Onduline (toiture légère pour les toits en pente), CB (écrans de protection pour façades et de sous-toiture pour toits inclinés) et Alwitra (systèmes détanchéité hautes performances pour les toits plats). Il dispose de 13 usines en France, Allemagne, Pologne, Espagne, Russie, États-Unis, Malaisie, Brésil et Turquie. Il réalise un chiffre daffaires consolidé de 350 M€ dans plus de 100 pays et emploie 2000 personnes de 34 nationalités différentes.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.